NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free EVGN Stock Alerts $0.63 -0.03 (-4.57%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.62▼$0.6750-Day Range$0.61▼$0.9852-Week Range$0.45▼$1.44Volume79,880 shsAverage Volume163,295 shsMarket Capitalization$25.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.62 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Evogene alerts: Email Address Evogene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside477.8% Upside$3.62 Price TargetShort InterestHealthy0.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector456th out of 908 stocksAgricultural Chemicals Industry8th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.17% of the outstanding shares of Evogene have been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently decreased by 19.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVGN. Previous Next 3.1 News and Social Media Coverage News SentimentEvogene has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Evogene this week, compared to 1 article on an average week.MarketBeat Follows5 people have added Evogene to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Evogene Stock (NASDAQ:EVGN)Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Read More EVGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVGN Stock News HeadlinesApril 24, 2024 | americanbankingnews.comEvogene (NASDAQ:EVGN) Share Price Crosses Below Two Hundred Day Moving Average of $0.74April 24, 2024 | americanbankingnews.comEvogene (NASDAQ:EVGN) Coverage Initiated at StockNews.comApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 11, 2024 | prnewswire.comBiomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual MeetingApril 2, 2024 | finance.yahoo.comEvogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food IndustryMarch 28, 2024 | prnewswire.comEvogene Announces Filing of Annual Report on Form 20-FMarch 20, 2024 | prnewswire.comEvogene Reports Receipt of Nasdaq Minimum Bid Price NotificationMarch 19, 2024 | prnewswire.comBayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse TestingApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 8, 2024 | finance.yahoo.comEvogene Ltd. (NASDAQ:EVGN) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comEVGN Stock Earnings: Evogene Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | de.investing.comEvogene: EPS übertrifft Schätzungen um 0,01 $ - Umsatz schlechter als erwartetMarch 7, 2024 | finance.yahoo.comEvogene Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | finanznachrichten.deAgPlenus Ltd.: AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel HerbicidesMarch 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from Evogene's earnings reportMarch 6, 2024 | benzinga.comEvogene Earnings PreviewMarch 6, 2024 | finance.yahoo.comAgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel HerbicidesMarch 5, 2024 | prnewswire.comCasterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed VarietiesFebruary 28, 2024 | prnewswire.comLavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement RequirementsFebruary 26, 2024 | finance.yahoo.comEvogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024February 26, 2024 | prnewswire.comEvogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024February 22, 2024 | prnewswire.comAgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive OfficerFebruary 21, 2024 | finanznachrichten.deBayer schwankt, deutliche Gewinnmitnahmen bei Renk, Zweifel um Nvidia und auch bei Super Micro Computer ist die Luft rausFebruary 21, 2024 | finance.yahoo.comAgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control SolutionFebruary 21, 2024 | prnewswire.comAgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control SolutionFebruary 20, 2024 | businesswire.comSyngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-InsecticideFebruary 20, 2024 | prnewswire.comSyngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-InsecticideSee More Headlines Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/26/2024Next Earnings (Estimated)5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Agricultural chemicals Sub-IndustryN/A Current SymbolNASDAQ:EVGN CUSIPN/A CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees142Year FoundedN/APrice Target and Rating Average Stock Price Target$3.62 High Stock Price Target$6.00 Low Stock Price Target$1.85 Potential Upside/Downside+470.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,880,000.00 Net Margins-423.39% Pretax Margin-460.76% Return on Equity-76.93% Return on Assets-45.13% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.95 Sales & Book Value Annual Sales$5.64 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.91Miscellaneous Outstanding Shares41,220,000Free Float38,166,000Market Cap$26.11 million OptionableOptionable Beta1.49 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ofer Haviv CPA (Age 58)CEO & President Comp: $390kDr. Nir Arbel (Age 44)Chief Product Officer Comp: $228kDr. Brian Ember (Age 48)Chief Executive Officer of AgPlenus Ltd Comp: $287kDr. Elran Hillel Haber M.B.A. (Age 44)Ph.D., Chief Executive Officer of Biomica Ltd Comp: $302kMr. Amit Noam Capt. res. (Age 42)Chief Executive Officer of Lavie Bio Ltd. Comp: $136kMr. Yaron Eldad (Age 59)Chief Financial Officer Mr. Mark Kapel (Age 47)Chief Technology Officer Comp: $276kRachel Pomerantz GerberHead of Investor RelationsMr. Sassi Masliah (Age 45)Vice President of Corporate Development Comp: $245kMs. Liat Foigel WejgmanVice President of Human ResourcesMore ExecutivesKey CompetitorsAcasti PharmaNASDAQ:ACSTSeaStar MedicalNASDAQ:ICUForte BiosciencesNASDAQ:FBRXSol-Gel TechnologiesNASDAQ:SLGLMovanoNASDAQ:MOVEView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 5,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions EVGN Stock Analysis - Frequently Asked Questions Should I buy or sell Evogene stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EVGN shares. View EVGN analyst ratings or view top-rated stocks. What is Evogene's stock price target for 2024? 3 brokers have issued 1 year price objectives for Evogene's shares. Their EVGN share price targets range from $1.85 to $6.00. On average, they predict the company's share price to reach $3.62 in the next twelve months. This suggests a possible upside of 477.8% from the stock's current price. View analysts price targets for EVGN or view top-rated stocks among Wall Street analysts. How have EVGN shares performed in 2024? Evogene's stock was trading at $0.84 at the beginning of 2024. Since then, EVGN shares have decreased by 25.5% and is now trading at $0.6259. View the best growth stocks for 2024 here. Are investors shorting Evogene? Evogene saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 69,700 shares, a decrease of 19.4% from the March 31st total of 86,500 shares. Based on an average daily trading volume, of 160,700 shares, the short-interest ratio is presently 0.4 days. View Evogene's Short Interest. When is Evogene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our EVGN earnings forecast. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) issued its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The biotechnology company earned $0.58 million during the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 423.39%. During the same quarter in the prior year, the company earned ($0.07) EPS. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Energy Transfer (ET), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Abbott Laboratories (ABT), Acasti Pharma (ACST) and Akari Therapeutics (AKTX). How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVGN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
